Europe – Page 55 – pharmaceutical daily

October 14, 2019 Off

Novartis to establish AI innovation lab with Microsoft to empower its associates to use AI across the business

Novartis will work with Microsogt to establish AI innovation lab to empower its associates to use AI across the business, on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) – starting with tackling personalized therapies for macular degeneration; cell & gene therapy; and drug design.

October 14, 2019 Off

Mogrify raises additional $16M, (total $20M) in series A funding

By BusinessWire

Mogrify has raised additional $16 million to advance its mission to transform the development of life-saving cell therapies, with initial…

October 14, 2019 Off

Novigenix and RadioMedix set to work on neuroendocrine cancer precision diagnostic test

By BusinessWire

Novigenix and RadioMEdix have announced collaboration on developing a test to measure response to radiopharmaceutical therapy, based on Novigenix’s technology.

October 10, 2019 Off

MGB Biopharma sees promising results from phase IIa clinical trial for potent oral bactericidal antibiotic targeting CDAD

By Dino Mustafić

MGB Biopharma has announced promising phase IIa clinical trial update for oral formulation MGB-BP-3, a potent oral bactericidal antibiotic targeting Clostridium Difficile-Associated Diarrhoea (CDAD), with – as it said in a press release – a completely novel mode of action.

October 10, 2019 Off

Heidelberg Pharma doubles revenue, net loss falls to €5.6, in first nine months

By Dino Mustafić

Heidelberg Pharma reported that its net loss for the first nine months of the fiscal year fell to €5.6 million from previous year’s €7.4 million, referring the result to the sales revenue and income totaling €6.7 million, from €3.5 million in the same period last year.

October 9, 2019 Off

Shionogi: cefiderocol met primary endpoint in phase III study in adults with nosocomial pneumonia

By BusinessWire

Shionogi has reported positive Results from Cefiderocol Phase III study in adults with nosocomial pneumonia caused by gram-negative pathogens, as cefiderocol met primary endpoint of non-inferiority in 14-day all-cause mortality compared to high-dose meropenem.

October 8, 2019 Off

Novartis gets FDA’s approval for Beovu for AMD patients

By Dino Mustafić

Novartis has received FDA approval for Beovu, the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy, for AMD patients, which are in risk from causes blindness and loss of independence.

October 7, 2019 Off

Biom’up’s Hemoblasttem Bellows approved in Australia

By Dino Mustafić

Biom’up SA, a specialist in surgical hemostasis, announces its flagship product, HEMOBLAST Bellows, has been approved for open as well as laparoscopic surgery by the Australian TGA regulatory authority for commercialization in the sizeable and growing Australian market.

October 7, 2019 Off

AveXis has early encouraging results for spinal muscular atrophy patients treatment

By Dino Mustafić

Novartis’ company Avexis said that it’s Phase 1/2 Srong study for intrathecal (IT) administration of AVXS-101, showed that patients aged 2 to 5, with spinal muscular atrophy (SMA) Type 2 achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold, at a mean duration of follow-up time of 9.3 months.

October 1, 2019 Off

Debiopharm’s novel IAP antagonist Debio 1143 met trial goals

By Dino Mustafić

Swiss-based biopharmaceutical drugmaker Debiopharm presented results for its novel IAP antagonist Debio 1143 from phase two trial, for high-risk Head and Neck cancer patients, which met its primary goal of increasing treatment efficacy compared to CRT and placebo.